In the present work, we tested RIC therapy in well-accepted preclinical settings of decreased NOS3 and comorbidity, reporting a translationally critical finding in stroke models that endothelial dysfunction and comorbidity abolish the benefits of RIC therapy. The gene discussed is NOS3; the disease is stroke disorder.